atezolizumab

Overview

Atezolizumab (MPDL3280A) is a humanized IgG1 monoclonal antibody that blocks PD-L1 (CD274), preventing its interaction with PD-1 and B7-1, thereby restoring anti-tumor T cell activity. FDA-approved for multiple tumor types including urothelial carcinoma, non-small cell lung cancer, and others.

Evidence in the corpus

  • 1 metastatic gallbladder carcinoma patient received atezolizumab among 12 ICI-treated patients in the MSK GBC cohort (n=233); overall 42% (5/12) ICI-treated patients showed evidence of response including 3 MSI-High, 1 MSS/TMB-high, and 1 MSS/TMB-low tumor PMID:36228155
  • Patients with ICI-high/TKI-low scores had significant PFS benefit from atezolizumab+bevacizumab vs. sunitinib in IMmotion151 (p=0.0003); the HiTME model classified 56% of ccRCC patients as ICI/ICI-combo-preferred PMID:22138691
  • Reviewed as part of the HCC therapeutic landscape; atezolizumab + bevacizumab achieved ORR 65% in 23 patients and received FDA breakthrough designation for HCC PMID:24798001
  • Cited as supporting context for checkpoint immunotherapy trials in nonmuscle invasive bladder cancer (NMIBC): high-grade NMIBC has mutational burden comparable to MIBC, and DDR-altered tumors carry markedly elevated burden (median 26 vs 8 mut/Mb, p<0.001); the established mutational-load → atezolizumab response link in metastatic urothelial carcinoma motivates ongoing PD-L1 inhibitor trials in NMIBC. PMID:28583311
  • Luminal-infiltrated MIBC (19% of TCGA cohort; high CD274/PD-L1, CTLA4, EMT markers; corresponds to TCGA Cluster-II) was previously reported to respond to anti-PD-L1 atezolizumab (Rosenberg et al. 2016) and may be resistant to cisplatin-based chemotherapy; this subtype is proposed as a positive biomarker for checkpoint blockade PMID:28988769
  • Included among the anti-PD-(L)1 regimens in the validation cohort (n=63 ccRCC) studied for PBRM1 LOF as a predictive biomarker; patients with biallelic PBRM1 loss had prolonged OS and PFS on anti-PD-(L)1 therapy PMID:29301960
  • One of the anti-PD-(L)1 agents evaluated in the 240-patient MSK NSCLC cohort; high TMB (above 50th percentile by MSK-IMPACT) associated with DCB across the cohort including atezolizumab-treated patients (DCB 38.6% vs 25.1%, p=0.009) PMID:29337640

Resistance mechanisms

Cancer types (linked)

  • GBC — used in metastatic gallbladder carcinoma; Stroma-rich molecular subtype and Excluded immune phenotype associated with ICI non-benefit
  • BLCA — DDR-high / high-TMB NMIBC profile motivates PD-L1 inhibitor trials, extrapolating from atezolizumab response associations in metastatic urothelial carcinoma.

Sources

  • PMID:36228155
  • PMID:28583311 — Pietzak et al. 2017, Cancer. MSK NMIBC MSK-IMPACT study; atezolizumab response association in metastatic urothelial carcinoma cited to motivate PD-L1 trials in DDR-high NMIBC.

This page was processed by entity-page-writer on 2026-05-15. - PMID:22138691

This page was processed by wiki-cli on 2026-05-06. - PMID:24798001

This page was processed by wiki-cli on 2026-05-11. - PMID:28988769

This page was processed by wiki-cli on 2026-05-15. - PMID:29301960

This page was processed by wiki-cli on 2026-05-15. - PMID:29337640

This page was processed by entity-page-writer on 2026-05-15.